Skip to content
2000
Volume 11, Issue 13
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The development of combretastatin as an antimitotic agent has led to an enormous effort to design other tubulin-targeting agents. The intriguing discovery that combretastatin A-4 phosphate causes selective damage to tumor vasculature has stimulated even more activity in this field. This attention to tubulin binding agents and their antivasculature activity is highly likely to lead to significant clinical advances for the treatment of cancer. This review focuses on the development of ketones as tubulin-binding agents such as chalcones and related enones as surrogates of combretastatin and colchicine.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612053764733
2005-05-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612053764733
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test